Početna › Srčani udar › Florida
Kliničke studije za Srčani udar u državi Florida
5 studija za Srčani udar traži sudionike na lokacijama u državi Florida.
Gradovi u državi Florida
Službeni tekst studije (engleski)
Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)
- - Boca Raton Regional - Research Physicians Network Alliance, Boca Raton
- Nova Clinical Research, LLC, Bradenton
- South Florida Nephrology Group, PA, Coral Springs
- i još 14
U tijeku regrutacijaFaza 2/3
Od 18 godina i više · Oba spola · Ažurirano 21. ruj 2026. · NCT05485961An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)
- Excel Medical Clinical Trials LLC, Boca Raton
- Bay Area Cardiology Assoc, Brandon
- Jacksonville Center for Clinical Research, Jacksonville
- i još 5
U tijeku regrutacijaFaza 3
Od 18 do 100 godina · Oba spola · Ažurirano 4. ruj 2026. · NCT07517263OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events
- Excel Medical Clinical Trials, Boca Raton
- Clearwater Cardiovascular Consultants, Clearwater
- Jacksonville Center for Clinical Research, Jacksonville
- i još 14
U tijeku regrutacijaFaza 3
Od 50 do 105 godina · Oba spola · Ažurirano 21. kol 2026. · NCT07136012Low Dose ColchicinE in pAtients With Peripheral Artery DiseasE to Address Residual Vascular Risk
- University of Florida - Gainesville, Gainesville
- Tampa General Hospital, Tampa
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 24. ožu 2026. · NCT04774159Focused Orticumab Research for Treating Inflammation in Coronary Arteries
- Abcentra Investigational Site, Boca Raton
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 27. sij 2026. · NCT06927739Iz ClinicalTrials.gov, podaci preuzeti 4. lis 2026.. Svaka studija ima svoje uvjete prihoda; tim studije odlučuje tko se može priključiti.